Antitumor effect of new conjugates of anthracycline antibiotic carminomycin bound to chitosan

Authors

  • Nedyalka Todorova Department of Biotechnology, University of Chemical Technology and Metallurgy, Sofia,
  • Maya Ilarionova National Centre of Oncology, Sofia,
  • Dimitar Todorov National Centre of Oncology, Sofia,

DOI:

https://doi.org/10.20450/mjcce.2007.269

Keywords:

carminomycin, pharmacokinetics, HL-60 cells, leukemia P388, leukemia L1210, chitosan, anthracycline antibiotics

Abstract

The antileukemic activities of two conjugates of the anthracycline antibiotic carminomycin – CX1 and CX2, were investigated. The direct cytotoxic efficacies of the two conjugates and free carminomycin (C), were measured by an MTT-assay which provides excellent reproducibility and statistical significance. The treatment of HL-60 cells with the three compounds for 48 and 96 hours showed considerable sensitivity to the free carminimycin, as well as to its conjugates CX1 and CX2. The ascetic form of leukemia P388 and leukemia L1210 (transplantation dose of 1·106 tumor cells) in hybrid mice BDF1 was used as leukemic models. All compounds investigated showed a maximal cytotoxic response and strong concentration dependence. By comparing the cytotoxic profile of carminomycin to those of CX1 and CX2, it can be assumed that a slower release of the active drug carminomycin have occurred. The criterion T/C showed a considerable antileukemic effect from 1.0 to 18.0 mg/kg. In conclusion, the conjugates CX1 and CX2 represent biologically active compounds with a putative depot-effect of slow release of the active intercalating agent carminomycin.

References

J. M. Terwogt, Clinical pharmacology of anticancer agents in relation to formulation and administration routs, Cancer Treatment Reviews, 25 (1), 83–101 (1999).

M. Fiallo, A. Laigle, M.N. Borrel, Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium with sensitive and resistant cells, Biochem. Pharm. 45 (3), 659–665 (1993).

P. S. Huang, A. Oliff, Drug-targeting strategies in cancer therapy, Curr. Opin. Genet. Dev., 11, 104–110 (2001).

T. N. Suratori, N. Hiroki, U. Kenichi, Conjugate of mitomycin C with N-succinylchitosan, J. Pharm., 1,120–130 (1993).

H. O. Pae, W. G. Seo, N. Y. Kim, G. S. Oh, G. E. Kim, Y. H. Kim, H. J. Kwak, Y. G. Yun, C. D., Jun, H. T. Chung. Induction of granulocytic differention in acute promyelocytic leukemia cells (HL-60) by water-soluble chitosan oligomer; Leukemia Research, 25, 339–346 (2001).

M. Krysteva, N. Todorova, K. Maneva, D. Todorov, Studies on the synthesis of antibiotic conjugates with chitosan, Biotech. Biotechnol. Eq., 11 (2), 30–33 (1997).

N. Todorova, M. Krysteva, K. Maneva, D. Todorov, Carminomycin- chitosan: a conjugated antitumor antibiotics, J. Bioactive Comp. Polym., 14 (1), 178–184 (1999).

H. K. Schmoll, K. Höffken, K. Possinger, Kompendium internistische Oncologie, Springer, Berlin, 1997, p. 2031.

Downloads

Published

2007-12-15

How to Cite

Todorova, N., Ilarionova, M., & Todorov, D. (2007). Antitumor effect of new conjugates of anthracycline antibiotic carminomycin bound to chitosan. Macedonian Journal of Chemistry and Chemical Engineering, 26(2), 147–150. https://doi.org/10.20450/mjcce.2007.269

Issue

Section

Biotechnology